Current treatment guidelines propose the usage of MMR after three months of TKI therapy as an indicator of the optimal response along with a predictor for MR, that is now an applicant marker for long-term success and discontinuation of therapy (50). well mainly because DNMT3A have already been most referred to as predating JAK2V617F mutations … Continue reading Current treatment guidelines propose the usage of MMR after three months of TKI therapy as an indicator of the optimal response along with a predictor for MR, that is now an applicant marker for long-term success and discontinuation of therapy (50)